Latest News

FDA rejects Immunomedics breast cancer drug, extending long regulatory drought

The 37-year drug development drought lives on.

Immunomedics (IMMU), the biotech founded in 1982, was informed by the Food and Drug Administration on Thursday night that its lead drug, an antibody drug conjugate to treat women with an aggressive form of breast cancer, could not be approved at this time.

Read the rest…

Source link

Related posts

Medical News Today: What's the link between 'hobbits' and modern humans?


Cardiac troponins and prediction of coronary artery disease risk


Medical News Today: The brain uses its 'autocorrect' feature to make out sounds


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy